Hemab Therapeutics Holdings, Inc. (COAG)

NASDAQ: COAG · Real-Time Price · USD

25.89

-0.41 (-1.56%)

At close: May 22, 2026, 4:00 PM EDT

27.02

+1.13 (4.36%)

After-hours: May 22, 2026, 6:37 PM EDT

COAG Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Selling, General & Admin	10.49	8.97
Research & Development	59.63	41.41
Total Operating Expenses	70.12	50.38
Operating Income	-70.12	-50.38
Interest Income	1.97	3.74
Other Non-Operating Income (Expense)	4.01	-1.88
Total Non-Operating Income (Expense)	5.98	1.86
Pretax Income	-64.14	-48.52
Provision for Income Taxes	-0.23	0.19
Net Income	-63.91	-48.71
Net Income to Common	-63.91	-48.71
Shares Outstanding (Basic)	1	1
Shares Outstanding (Diluted)	1	1
EPS (Basic)	-67.56	-51.49
EPS (Diluted)	-67.56	-51.49
Shares Outstanding	0.95	0.95
EBIT	-70.12	-50.38

Updated May 21, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q